更多栏目
搜索
China Market Approval Tracker: Feb 2021
储旻华·2021-03-29
PharmaDJ
Six NMEs Get Market Approval in China.

China Market Approval Tracker: Feb 2021


Writer: Minhua Chu

Editor: Justin Fischer


Six new molecular entities (NME) received market approval in China in Feburary 2021, including three COVID-19 vaccines developed by Chinese companies.


Gilteritinib, a new oral drug for acute myelod leukemia (AML) therapy, was granted conditional market authorization by China’s National Medical Products Administration (NMPA). It was developed by Japanese pharmaceutical company Astellas and was approved as a therapy for relapsed or refractory AML adult patients carrying FLT3 mutations.


AML patients with FLT3 mutation often have a very poor prognosis, with the median survival of less than six months after salvage chemotherapy. Moreover, the status of FLT3 mutations may change during AML treatment or even after relapse. As FMS-like tyrosine kinase 3 (FLT3), gilteritinib has shown significant inhibition of two common FLT3 mutations - FLT3-ITD and FLT3-TKD, which is found in approximately one third of AML patients.


Before the new leukemia drug was launched in China on December 16, Astellas had already reached a cooperation agreement with Chinese company Baheal on the import and distribution of the drug. In the near future, the drug can enter China directly from Japan via air or sea through the port of Qingdao.


gaitubao_1.jpeg


Bristol-Myers Squibb's (BMS) subsidiary Celegene submitted a marketing application for Luspatercept for Injection in China. It was accepted by the Center for Drug Evaluation (CDE) under NMPA. The drug is a red blood cell maturation agent for beta-thalassemia adult patients who require regular red blood cell (RBC) infusions.


According to BMS, Luspatercept is the company's first innovative hematology drug to be granted a priority review designation following the submission of offshore clinical trial data to the China CDE.


gaitubao_2 (1).png


Also, Junshi Biosciences (HK: 1877; SH: 688180) submitted an application to extend the labels of its only marketed product, anti-PD-1 antibody toripalimab, to first-line NSCLC and stage III nasopharyngeal carcinoma (NPC). This is the first application of PD-1 antibodies for NPC indication.


文章关键字:new molecular entities (NME),COVID-19 vaccine,Gilteritinib,acute myelod leukemia (AML),Astellas,FLT3 mutation,FMS-like tyrosine kinase 3 (FLT3),Baheal,the Center for Drug Evaluation (CDE),NMPA
1520
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2020 研发客.All Rights Reserved.
建议反馈: Support@PharmaDJ.com
备案/许可证编号: 沪ICP备17054709号-1
联系电话:021 - 88194359